Francisco J. Esteva: The clinical applications of PARPi across various cancers
Francisco J. Esteva, Professor of Medicine at the Zucker School of Medicine, posted on LinkedIn about recent paper by Chadi Hage Chehade et al., titled “A pan-tumor review of the role of poly (adenosine diphosphate ribose) polymerase inhibitors” published on ASC Journals.
Authors: Chadi Hage Chehade, Georges Gebrael, Nicolas Sayegh, Zeynep Irem Ozay, Arshit Narang, Tony Crispino, Talia Golan, Jennifer K. Litton, Umang Swami, Kathleen N. Moore, Neeraj Agarwal
“New review article on PARP inhibitors is out! This comprehensive overview summarizes the clinical applications of PARPi across various cancers, including prostate, ovarian, breast, and pancreatic cancers. Learn about the latest approved indications and combination strategies. Very informative!
Key highlights:
- Prostate Cancer: Treatment options for metastatic castrate-resistant prostate cancer with HRR mutations, including talazoparib + enzalutamide, abiraterone + niraparib/olaparib, olaparib, and rucaparib.
- Ovarian Cancer: First-line maintenance therapy options like olaparib, olaparib + bevacizumab, and niraparib. The article also discusses the latest regulatory approvals for rucaparib.
- Breast Cancer: Adjuvant and metastatic settings for olaparib and talazoparib in HER2-negative breast cancer with germline BRCA1/2 mutations.
- Pancreatic Cancer: Maintenance olaparib for patients with germline BRCA1/2 mutations and platinum-sensitive metastatic disease.
Read the full article to stay up-to-date on the evolving landscape of PARP inhibitor therapies!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023